|
1.
|
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. MedStar authors:
Year: 2019
Citation: - Lancet Oncology. 20(1):88-99, 2019 01.
Institution: - MedStar Franklin Square Medical Center
Medline publication type:
All authors: - Bandos H, Brufsky AM, Chia SK, Dakhil SR, Fehrenbacher L, Geyer CE Jr, Graham ML, Jeong JH, Lembersky BC, Mamounas EP, McCarron EC, Paik S, Rastogi P, Seay TE, Soori GS, Swain SM, Wade JL 3rd, Walshe JM, Wickerham DL, Wolmark N
|
|
2.
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(6):461-71, 2013 May.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|